ROP Treatment for Premature Infants | PristynCare

Risk Factors

Premature infants at greatest risk of developing ROP include those with:

• Gestational age below 28 weeks
• Birth weight below 1000 grams
• Need for prolonged oxygen supplementation
• Sepsis, intraventricular hemorrhage, or respiratory distress syndrome
• Multiple organ complications in the neonatal period

Candidacy for Treatment

Treatment is recommended for ROP at threshold or pre-threshold stages, particularly Stage 3 in Zone I or Zone II with plus disease, and any Stage 4 or Stage 5 disease. All premature infants below 32 weeks or under 1500 grams must undergo mandatory retinal screening regardless of symptoms.

Diagnosis

ROP screening and diagnosis involves:

• Indirect ophthalmoscopy by a trained retinal specialist or pediatric ophthalmologist
• Wide-field retinal imaging systems such as RetCam
• Screening begins at 4 weeks of age or 31 weeks postmenstrual age, whichever is later
• Follow-up examinations every 1 to 3 weeks based on severity
• Fundus photography and documentation of zone, stage, and extent

Treatment Options

The main treatments for ROP include laser photocoagulation to destroy avascular retinal tissue and prevent abnormal vessel growth. Intravitreal anti-VEGF injections (bevacizumab or ranibizumab) are increasingly used for aggressive posterior ROP or Zone I disease. For advanced stages with retinal detachment, scleral buckling or vitrectomy may be needed to reattach the retina and restore potential vision.

ROP Laser Treatment Steps

Laser photocoagulation for ROP is performed under general anesthesia in a neonatal intensive care setting:

• The infant is sedated and the pupils are dilated with eye drops
• A lid speculum is placed to keep the eye open
• Indirect ophthalmoscopy is used to visualize the peripheral retina
• Laser burns are applied to the avascular retina anterior to the ridge
• The entire avascular zone is treated in one session if possible
• Post-procedure, the infant is monitored in the NICU
• Follow-up examination is performed within 1 to 2 weeks to assess response
• Anti-VEGF injections may be combined with or used instead of laser for aggressive cases

Post-Treatment Care

Post-treatment monitoring for ROP requires:

• Regular retinal examinations every 1 to 4 weeks after treatment
• Monitoring for disease regression or reactivation
• Systemic health monitoring in the NICU environment
• Long-term annual eye exams for refractive errors, strabismus, and amblyopia
• Vision therapy and glasses as needed during childhood development

Risks and Complications of ROP Treatment

Risks associated with ROP treatment include:

• Refractive errors: Myopia and astigmatism are common after laser treatment
• Strabismus: Misalignment of the eyes may develop following treatment
• Amblyopia: Reduced vision in one eye if not detected and treated early
• Retinal detachment despite treatment: Progressive stages may not respond fully to laser
• Anesthetic risks: Associated with general anesthesia in premature infants
• Anti-VEGF systemic effects: Potential impact on systemic vascular development in very preterm infants